Compare JSPR & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JSPR | SCNX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | 22 | 19 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 19.0M |
| IPO Year | N/A | N/A |
| Metric | JSPR | SCNX |
|---|---|---|
| Price | $0.92 | $0.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $15.50 | $1.50 |
| AVG Volume (30 Days) | 651.8K | ★ 705.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $0.24 |
| 52 Week High | $7.19 | $2.60 |
| Indicator | JSPR | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 49.94 |
| Support Level | $0.62 | $0.38 |
| Resistance Level | $1.12 | $0.48 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 54.08 | 54.41 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.